# Two Drug Leads Show Potent Anticancer Activity

*Centrose to Present at BIO 2008*

Brief: Centrose is announcing today that two of its lead compounds have been found to have potent antitumor efficacy against colorectal and non-small cell lung cancers.

MADISON, Wis., June 3, 2008 - Centrose, a Madison, Wis.-based biopharmaceutical company, is applying scientific breakthroughs in sugar chemistry to the discovery, development and commercialization of small molecule therapeutics. Centrose announced today that two of its lead compounds have been found to have potent antitumor efficacy against colorectal and non-small cell lung cancers. In animal models, the human tumors were shown to undergo complete remission after lead drugs manufactured at Centrose were administered. "We are very pleased with the results as they clearly show how novel sugar chemistry can drastically change drug activity" states Chief Scientific Officer Dr. C. Richard Hutchinson. In addition to these results, recent screening data has also prompted the National Cancer Institute to proceed with canine toxicity studies to further assess these compounds. Their preliminary results show that the toxicity is considerably less than the parent drug of which Centrose enhanced.

Centrose intends on using the results, along with its other lead programs to boost company value and open its Series A financing round. “We will take this data to BIO in San Diego and look to find the appropriate financing groups to help us fund pre-clinical studies in order to move to the next stage – studies in people that need better anti-cancer therapies”, states Chief Executive Officer Dr. James Prudent. Centrose will be presenting the data in a scientific poster presentation at the innovation Corridor of the BIO convention as well as giving two oral presentations on the Company. One of those presentations will be at the BIO partnering forum where Centrose accepted an offer to present. The other presentation will be at the Wisconsin Pavilion on the exposition floor.

About Centrose: Centrose delivers commercially relevant technology for the attachment of any sugar molecule to any compound. Sugars are critical to the regulation of biological processes and pathways in the human body, and play fundamental roles in drug action. Naturally derived drugs such as erythromycin, a commonly used antibiotic, that contain sugar molecules have been found to be inactive after the sugars were removed and enhanced in activity when new sugars were added. Centrose owns exclusive chemistry that will allow it’s chemists to exploit the power of sugar chemistry in much the same way that nature does. Recent data suggests that new drugs containing sugar attachments will find their way to market more quickly, since fewer failures are expected. Centrose owns a broad set of patents and patent applications covering novel drug leads and platform methodology.

**Contacts:**
James Prudent, Ph.D.
Chief Executive Officer,
Centrose LLC
(608) 209-8933